King's College London psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
King's College London is listed with 7 registered studies counted here, in London, United Kingdom. By compound: 4 psilocybin and 3 ketamine. By registry status: 1 active, not recruiting and 6 completed. By phase: 1 early phase 1, 1 phase 2, 4 not applicable and 1 not reported. Reported start years run from 2014 (earliest) to 2024 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 7 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Active, not recruiting | 1 | 14% |
| Completed | 6 | 86% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 14% |
| Phase 2 | 1 | 14% |
| Not applicable | 4 | 57% |
| Not reported | 1 | 14% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin in Functional Neurological Disorder | NCT05723276 | Completed | Not applicable | 2024-02-14 | Psilocybin |
| Psilocybin in Adults With and Without Autism Spectrum Disorder | NCT05651126 | Completed | Not applicable | 2022-12-12 | Psilocybin |
| Synaptic Imaging and Network Activity in Treatment Resistant Depression | NCT05870501 | Completed | Not applicable | 2021-10-20 | Ketamine |
| Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine | NCT04977674 | Completed | Early Phase 1 | 2021-09-27 | Ketamine |
| Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin | NCT07164755 | Active, not recruiting | Not reported | 2021-06-21 | Psilocybin |
| Psilocybin in Depression Resistant to Standard Treatments | NCT04959253 | Completed | Phase 2 | 2020-09-01 | Psilocybin |
| Ketamine's Actions on Rumination Mechanisms as an Antidepressant | NCT04656886 | Completed | Not applicable | 2014-09-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.